Lianet Suarez Garcia
Family · Pembroke Pines, FLNPI 1407562150
Payments from drug & device makers
Across 95 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$345
- AstraZeneca$326
- Novo Nordisk$284
- Exact Sciences$206
- GSK$111
- Idorsia Pharmaceuticals US Inc$89
- plus $565 from 17 others
What the payments were for
- Food & beverage$1,927100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 21 | $345 |
| AstraZeneca | 11 | $326 |
| Novo Nordisk | 15 | $284 |
| Exact Sciences | 9 | $206 |
| GSK | 6 | $111 |
| Idorsia Pharmaceuticals US Inc | 5 | $89 |
| AbbVie | 4 | $70 |
| Pfizer | 3 | $66 |
| Amgen | 3 | $52 |
| Medtronic | 1 | $48 |
| Bayer | 2 | $44 |
| Abbott | 2 | $41 |
| Verity Pharmaceuticals Inc. | 2 | $35 |
| Phadia US Inc. | 2 | $34 |
| Corcept Therapeutics | 1 | $26 |
| Novartis | 1 | $24 |
| Intra-sana Laboratories | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Biogen | 1 | $18 |
| IBSA Pharma Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Corium, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$125
How this compares
$1,927 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 15 | $23,866 |
| OzempicSemaglutide | 24 | $20,955 |
| MounjaroTirzepatide | 17 | $20,304 |
| TrulicityDulaglutide | 11 | $10,478 |
| Omeprazole | 22 | $702 |
| ValacyclovirValacyclovir Hcl | 11 | $520 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $520 |
| Levothyroxine Sodium | 37 | $416 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $416 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 18 | $333 |
| Losartan Potassium | 38 | $304 |
| Atorvastatin Calcium | 39 | $293 |
| Rosuvastatin Calcium | 37 | $234 |
| Gabapentin | 15 | $211 |
| Amlodipine Besylate | 29 | $200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $345 | $30,78228 claims |
| Novo NordiskOzempic | $284 | $20,95524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Pembroke Pines
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.